TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Healthy Men to Compare 2 Different Formulations of Alteplase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests~* Age of 18 to 45 years (inclusive)~* Body mass index (weight divided by height squared) (BMI) of 18.5 to 29.9 kg/m2 (inclusive)~* Body weight of 65 - 100 kg (inclusive) at screening~* Signed and dated written informed consent prior to admission to the study, in accordance with Good Clinical Practice (GCP) and local legislation~Exclusion Criteria:~* Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator~* Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm~* Any laboratory value outside the reference range that the investigator considers to be of clinical relevance, e.g. thrombotic predisposition according to thrombophilic testing~* Any evidence of a concomitant disease assessed as clinically relevant by the investigator~* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders~* Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders~* History of relevant orthostatic hypotension, fainting spells, or blackouts~* Chronic or relevant acute infections~* History of relevant allergy or hypersensitivity~* During COVID-19 pandemic: laboratory test indicative of an ongoing SARS-CoV-2 infection Further exclusion criteria apply.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Part B: Alteplase, TPA-02 then Alteplase, TPA-05 (Type: EXPERIMENTAL): None
- Part B: Alteplase, TPA-05 then Alteplase, TPA-02 (Type: ACTIVE_COMPARATOR): None
- Part A: Alteplase, TPA-05 then Alteplase, TPA-02 (Type: EXPERIMENTAL): Open-label
- Part A: Alteplase, TPA-02 then Alteplase, TPA-05 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations~Exclusion Criteria:~* Any significant acute or chronic medical illness~* Any history or evidence of abnormal bleeding or coagulation disorders, intracranial hemorrhage, or abnormal bleeding (including heavy menstrual bleeding that has resulted in anemia within the past 1 year) or coagulation disorders in a first degree relative

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Arm A: Apixaban (Type: EXPERIMENTAL): Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via oral syringe
- Arm B: Apixaban (Type: EXPERIMENTAL): Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via nasogastric tube (NGT) immediately followed by 60 mL of D5W via NGT
- Arm C: Apixaban (Type: EXPERIMENTAL): Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via NGT immediately followed by 60 mL of infant formula via NGT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Histologically or cytologically confirmed diagnosis of squamous cell or poorly differentiated carcinomas of the head and neck or lymphoepithelioma~* Prior radiation to the head and neck, surgery or chemotherapy is allowed~* Karnofsky performance status of \>= 70%~* Intact organ and bone marrow function~* Obtained informed consent~Exclusion Criteria:~* Demonstration of metastatic disease (i.e. M1 disease).~* Incomplete healing from previous surgery~* Pregnancy or breast feeding (men and women of child-bearing potential are eligible but must consent to using effective contraception during therapy and for at least 3 months after completing therapy)~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Patients with clinically significant pulmonary dysfunction, cardiomyopathy, or any history of clinically significant CHF are excluded. The exclusion of patients with active coronary artery disease will be at the discretion of the attending physician.~* Uncontrolled active infection unless curable with treatment of their cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- erlotinib + celecoxib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prednisone for Heart Failure Patients With Hyperuricemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-70 years old~* NYHA Class III-IV~* EF =\< 40%~* Uric acid =\> 9.5 mg/dL~Exclusion Criteria:~* Acute gouty arthritis~* Any condition (other than CHF) that could limit the use of prednisone or allopurinol~* Any concurrent disease likely to limit life expectancy.~* Active myocarditis, or an obstructive or restrictive cardiomyopathy~* Heart Attack, Stroke, Unstable Angina or Cardiac surgery within previous 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- prednisone (Type: EXPERIMENTAL): None
- allopurinol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Dose escalation cohorts: Patients with histologically or cytologically confirmed diagnosis of malignancy (including lymphoma) with demonstrated progression of a tumor for whom there is no available therapy likely to convey clinical benefit AND who have not been previously treated with a PD-1/PD-L1 inhibitor. These patients do not require measurable disease~* Dose expansion cohorts: Patients with histologically or cytologically confirmed diagnosis of 1 of specified tumors with measurable disease per RECIST 1.1 or Lugano criteria. Some patients may have been previously treated with a PD-1 or PD-L1 inhibitor~* Eastern Cooperative Oncology Group performance status of 0 or 1~* Adequate organ and bone marrow function~Key Exclusion Criteria:~* Prior treatment with any LAG-3 targeting biologic or small molecule~* Radiation therapy within 2 weeks prior to randomization and not recovered to baseline from any AE due to radiation~* Untreated or active central nervous system metastases - Ongoing or recent (within 5 years) evidence of significant autoimmune disease~* Corticosteroid therapy (\>10 mg prednisone/day or equivalent) within 1 week prior to the first dose of study drug~* Myocardial infarction within 6 months~Note: Other protocol defined Inclusion / Exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monotherapy (REGN3767) (Type: EXPERIMENTAL): Group A will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition 1 tumor-specific cohort will be treated at the recommended phase 2 dose (RP2D) during dose expansion.
- Combination Therapy (REGN3767+cemiplimab) (Type: EXPERIMENTAL): Group B will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition, 9 tumor-specific cohorts will be treated at the RP2D during dose expansion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Donepezil and the Risk of Falls in Seniors With Cognitive Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 65-100~* Male or Female~* Having Mild Cognitive Impairment (diagnosed using criteria validated by Petersen et. al)~* Acceptable Body Mass Index (BMI) range: 18-30~* Acceptable blood pressure (Systolic: 110-160, Diastolic: 50-110)~* Able to walk independently 10 meters without any gait aid~* Able to travel to Aging Brain and Memory Clinic for the assessments~Exclusion Criteria:~* Unable to understand English~* Low body weight (less than 99lb/45kg)~* Possible diagnosis of Alzheimer's Disease~* Use of herbal preparations such as St. John's Wort and ginko biloba~* History of drug or alcohol abuse/dependence~* History of psychiatric illness within the last two years, including depression~* Parkinsonism or any neurological disorder with residual motor deficit (e.g.: stroke, epilepsy)~* Musculoskeletal disorder detected by clinical examination which affects gait performance~* Active osteoarthritis affecting the lower limbs (American College of Rheumatology criteria)~* Use of psychotropic medication, which can affect motor performance~* Use of an anticholinergic agent (benztropines), other acetylcholinesterase inhibitors or cholinergic agents (bethanechol)~* Depression (score above 8/15 on the Geriatric Depression Scale - GDS)~* Comorbidities which may contradict use of ChEIs~* History of chronic bradycardia or sick sinus syndrome~* Severe COPD and/or asthma~* History of seizure disorders

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Donepezil (Type: EXPERIMENTAL): participants with MCI receiving donepezil
- Placebo (Type: PLACEBO_COMPARATOR): Participants with MCI receiving placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Japanese adults aged 20 to 60 years~Exclusion Criteria:~* History of anaphylaxis, serious vaccine reactions, hypersensitivity to vaccine viral proteins or excipients~* Administration of adjuvanted influenza vaccine or suspected influenza disease within 3 month prior to study start~* Administration of any other vaccines within 4 weeks prior to enrollment expect for seasonal influenza vaccines within 1 week~* History of progressive or severe neurological disorders

- Gender: ALL
- Minimum Age: 29 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: OTHER): Dose ranging
- Arm 2 (Type: OTHER): Dose ranging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant female~* Females of child-bearing potential must practice a medically accepted form of birth control~Exclusion Criteria:~* Currently exhibiting an acute upper respiratory tract infection~* history of chronic respiratory disease requiring regular therapy(i.e. COPD, asthma, bronchitis, etc.)~* any condition likely to increase the risk of severe or complicated influenza (i.e. cardiac disease, chronic renal disease, endocrine diseases, including diabetes and/or immunosuppressive therapy)~* any condition requiring regular treatment with antihistamines, analgesics or antipyretics~* known infection with HIV, hepatitis B virus or hepatitis C virus~* any other serious, uncontrolled disease~* any active infections requiring use of antibiotic or antiviral drugs~* non-ambulatory status~* suspected drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Interferon-alpha (Type: EXPERIMENTAL): 150 international units of interferon-alpha
- placebo (Type: PLACEBO_COMPARATOR): placebo lozenges

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Symptoms and signs of indication of lymphocytic colitis~Exclusion Criteria:~* Infectious diarrhoea,~* Diarrhoea as a result of the presence of other symptomatic organic disease(s) of the gastrointestinal tract or endoscopic-histological findings Celiac disease~* Pregnancy or breast-feeding,~* Participation in an other clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Budesonide
- B (Type: EXPERIMENTAL): Mesalazine
- C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with histologically- or cytologically-confirmed non-squamous non-small cell lung cancer~* Subjects who received a diagnosis of stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation according to the UICC-TNM Classification (7th edition) with no prior systemic anticancer therapy~* Subjects with at least one measurable lesion by radiographic tumor assessments per RECIST 1.1 criteria~* Subjects who are able to provide tumor tissue specimens.~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1~Exclusion Criteria:~* Subjects with known EGFR mutations, including deletions in exon 19 and exon 21 (L858R) substitution mutations.~* Subjects with known ALK translocations.~* Complication or history of severe hypersensitivity reactions to antibody products or platinum-containing compounds~* Subjects with autoimmune disease or known chronic or recurrent autoimmune disease.~* Subjects with multiple cancer.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ONO-4538 group (Type: EXPERIMENTAL): ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent by a parent or guardian prior to any study-related procedures.~* When applicable, informed assent (as deemed appropriate by the Institutional Review Board \[IRB\]) by the participant prior to any study-related procedures.~* Participant completed Study SHP633-302 (NCT02980666).~* Participant (and/or parent/guardian) understands and is willing and able to fully adhere to study requirements as defined in this protocol.~Exclusion Criteria:~There are no exclusion criteria for this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teduglutide (Type: EXPERIMENTAL): Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24-week intervals. If a participant deteriorates during a follow-up period, the participant may be evaluated immediately for additional teduglutide treatment (24-week interval) until teduglutide is commercially available for each participant, the participant's participation in this study is discontinued, or the study is discontinued.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Inadequate blood sugar control~Exclusion Criteria:~* Previous treatment for diabetes~* Current treatment with other medications to lower blood sugar~* Major heart, liver or kidney problems~* Women who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin 2.5 mg QAM (A) (Type: EXPERIMENTAL): PLUS open-label metformin (as needed as rescue medication)
- Saxagliptin 2.5 mg titrated to 5 mg QAM (B) (Type: EXPERIMENTAL): PLUS open-label metformin (as needed as rescue medication)
- Saxagliptin 5 mg QAM (C) (Type: EXPERIMENTAL): PLUS open-label metformin (as needed as rescue medication)
- Saxagliptin 5 mg QPM (D) (Type: EXPERIMENTAL): PLUS open-label metformin (as needed as rescue medication)
- Placebo (E) (Type: PLACEBO_COMPARATOR): PLUS open-label metformin (as needed as rescue medication)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete